Silicosis is an incurable and progressive
lung disease characterized by chronic
inflammation and fibroblasts accumulation. Studies have indicated a vital role for epithelial-mesenchymal transition (EMT) in fibroblasts accumulation. NLRP3
inflammasome is a critical mediator of
inflammation in response to a wide range of stimuli (including
silica particles), and plays an important role in many
respiratory diseases. However, whether NLRP3
inflammasome regulates
silica-induced EMT remains unknown. Our results showed that
silica induced EMT in human bronchial epithelial cells (16HBE cells) in a dose- and time-dependent manner. Meanwhile,
silica persistently activated NLRP3
inflammasome as indicated by continuously elevated extracellular levels of interleukin-1β (IL-1β) and
IL-18. NLRP3
inflammasome inhibition by
short hairpin RNA (
shRNA)-mediated knockdown of NLRP3, selective inhibitor
MCC950, and
caspase-1 inhibitor Z-YVAD-FMK attenuated
silica-induced EMT. Western blot analysis indicated that TAK1-MAPK-Snail/NF-κB pathway involved NLRP3
inflammasome-mediated EMT. Moreover,
pirfenidone, a commercially and clinically available drug approved for treating
idiopathic pulmonary fibrosis (IPF), effectively suppressed
silica-induced EMT of 16HBE cells in line with NLRP3
inflammasome inhibition. Collectively, our results indicate that NLRP3
inflammasome is a promising target for blocking or retarding EMT-mediated
fibrosis in pulmonary
silicosis. On basis of this mechanism,
pirfenidone might be a potential drug for the treatment of
silicosis.